Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572906 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
A Phase 2 study of Peripheral Nerve Injuries, sponsored by Neuraptive Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 10
- Study locations
NCT04572906: Completed Phase 2 study of Peripheral Nerve Injuries, sponsored by Neuraptive Therapeutics.
NCT04572906 is a Phase 2 study of Peripheral Nerve Injuries that has completed, run by Neuraptive Therapeutics. The registered enrollment target is 51 participants, below the 456-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04572906, a Phase 2 study of Peripheral Nerve Injuries, has completed, sponsored by Neuraptive Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 10
- Study locations
Study Summary
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.
Primary Outcome
An adverse event is any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given a study product or in a clinical study. A treatment-emergent adverse event was defined as any adverse event that newly appeared, increased in frequency, or worsened in severity on or after the exposure to the study product.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NTX-001
Study Locations (10)
Florida
- UF Health - University of FL - Gainesville - Gainesville
- Orlando Health - Orlando
Maryland
- Curtis National Hand Center - Baltimore
- Johns Hopkins Bayview Medical Center - Baltimore
Illinois
- University of Chicago - Chicago
Indiana
- Indiana Hand to Shoulder Center - Indianapolis
Missouri
- Washington University - St Louis
Ohio
- The Ohio State University Wexner Medical Center Hand and Upper Extremity Center - Columbus
Virginia
- Virginia Commonwealth University - Richmond
Washington
- Harborview Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 2 |
What the finished NCT04572906 record still lists
NCT04572906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 456-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Peripheral Nerve Injuries appearing as the primary indexed condition, and to 1 intervention - of which NTX-001 is the first listed.
NCT04572906 lists 10 locations in 8 states (Florida, Maryland, Illinois).
Frequently Asked Questions
What is clinical trial NCT04572906 about?
NCT04572906 is a clinical study titled "Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries". NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.
What is the current status of trial NCT04572906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-09-25. Estimated completion is 2024-06-27.
What conditions does trial NCT04572906 study?
This clinical trial studies the following conditions: Peripheral Nerve Injuries.
What interventions are being tested in trial NCT04572906?
The interventions under investigation include: NTX-001 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04572906?
This trial is sponsored by Neuraptive Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04572906 being conducted?
This trial has 10 study locations across Florida, Illinois, Indiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nerve Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04572906's enrollment target sits among peer trials
51 7th of 8 higher than 2 of 8 other Peripheral Nerve Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Nerve Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
RECRUITING · Phase 2
-
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
RECRUITING · Phase 2
-
Harnessing Neuroplasticity to Enhance Functional Recovery During Chronic Recovery From Upper Extremity Nerve Repair
RECRUITING · NA
-
Promoting Healing of Injured Nerves With Electrical Stimulation Therapy
RECRUITING · NA
-
Upper Extremity Functional Electrical Stimulation (FES) for Restoration of Upper Extremity Function After Spinal Cord Injury (SCI)
RECRUITING · NA
-
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI